menu
    • menu
    [{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Liraglutide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"VENT-01","moa":"NLRP3","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Gubra","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide","year":"2025","type":"Licensing Agreement","leadProduct":"GUB014295","moa":"Amylin receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Gubra","amount2":2.23,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":2.23,"dosageForm":"Subcutaneous Injection","sponsorNew":"Gubra \/ AbbVie Inc","highestDevelopmentStatusID":"6","companyTruncated":"Gubra \/ AbbVie Inc"},{"orgOrder":0,"company":"Gubra","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"GUB014295","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Gubra","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Gubra \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Gubra \/ Inapplicable"},{"orgOrder":0,"company":"Gubra","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"GUB014295","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Gubra","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Gubra \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Gubra \/ Inapplicable"},{"orgOrder":0,"company":"Antag Therapeutic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"AT-7687","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Antag Therapeutic","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Antag Therapeutic \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Antag Therapeutic \/ Inapplicable"},{"orgOrder":0,"company":"Antag Therapeutic","sponsor":"Versant Ventures","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide","year":"2024","type":"Series A Financing","leadProduct":"AT-7687","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Antag Therapeutic","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Antag Therapeutic \/ Versant Ventures","highestDevelopmentStatusID":"6","companyTruncated":"Antag Therapeutic \/ Versant Ventures"},{"orgOrder":0,"company":"Cytoki Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"CK-0045","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Cytoki Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cytoki Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cytoki Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Cytoki Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"CK-0045","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Cytoki Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cytoki Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cytoki Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Gubra","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"BI 1820237","moa":"||Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Gubra","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gubra \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"6","companyTruncated":"Gubra \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Antag Therapeutic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide","year":"2025","type":"Inapplicable","leadProduct":"AT-7687","moa":"GIP receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Antag Therapeutic","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Antag Therapeutic \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Antag Therapeutic \/ Inapplicable"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Antag Therapeutic

                            Denmark arrow
                            EPS
                            Not Confirmed

                            Antag Therapeutic

                            Denmark arrow
                            EPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AT-7687

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Antag Starts Phase 1a Trial of GIPR Antagonist AT-7687 for Obesity

                            Details : AT-7687 is a peptide GIP receptor antagonist designed for once-weekly subcutaneous, currently, it is being evaluated in the treatment of obesity.

                            Product Name : AT-7687

                            Product Type : Peptide

                            Upfront Cash : Inapplicable

                            April 02, 2025

                            Lead Product(s) : AT-7687

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Gubra

                            Denmark arrow
                            EPS
                            Not Confirmed

                            Gubra

                            Denmark arrow
                            EPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : GUB014295

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : Phase I

                            Sponsor : AbbVie Inc

                            Deal Size : $2,225.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            AbbVie, Gubra Sign License Deal to Develop Amylin Analog for Obesity

                            Details : Under the licensing agreement, Abbvie will hold the exclusive rights to develop GUBamy (GUB014295), a potential best-in-class, long-acting amylin analog for the treatment of obesity.

                            Product Name : GUBamy

                            Product Type : Peptide

                            Upfront Cash : $350.0 million

                            March 03, 2025

                            Lead Product(s) : GUB014295

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Phase I

                            Sponsor : AbbVie Inc

                            Deal Size : $2,225.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Gubra

                            Denmark arrow
                            EPS
                            Not Confirmed

                            Gubra

                            Denmark arrow
                            EPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : GUB014295

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Gubra reveals early data for once-weekly obesity asset

                            Details : GUBamy (GUB014295) is a long-acting amylin agonist for once weekly subcutaneous administration. It is under phase 1 clinical development for the potential treatment of obesity.

                            Product Name : GUBamy

                            Product Type : Peptide

                            Upfront Cash : Inapplicable

                            November 13, 2024

                            Lead Product(s) : GUB014295

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Gubra

                            Denmark arrow
                            EPS
                            Not Confirmed

                            Gubra

                            Denmark arrow
                            EPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BI 1820237,BI 456906

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : Phase I

                            Sponsor : Boehringer Ingelheim GmbH

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Boehringer Drops Obesity Drug from Gubra Partnership

                            Details : BI 1820237 is a potent, specific peptidic NPY2R agonist in development for the treatment of overweight/obesity via once-weekly subcutaneous injection

                            Product Name : BI 1820237

                            Product Type : Peptide

                            Upfront Cash : Inapplicable

                            October 31, 2024

                            Lead Product(s) : BI 1820237,BI 456906

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Phase I

                            Sponsor : Boehringer Ingelheim GmbH

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Novo Nordisk

                            Denmark arrow
                            EPS
                            Not Confirmed

                            Novo Nordisk

                            Denmark arrow
                            EPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Liraglutide

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Novo's Older Obesity Drug is Safe and Effective for Children, Study Finds

                            Details : Saxenda is a GLP-1 receptor agonist indicated as an adjunct to a reduced-calorie diet and increased physical activity being investigated for chronic weight management in 6-12 years old patients.

                            Product Name : Saxenda

                            Product Type : Peptide

                            Upfront Cash : Inapplicable

                            October 09, 2024

                            Lead Product(s) : Liraglutide

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Novo Nordisk

                            Denmark arrow
                            EPS
                            Not Confirmed

                            Novo Nordisk

                            Denmark arrow
                            EPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Amycretin

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Novo Nordisk Experimental Obesity Pill Has Mild-To-Moderate Side Effects in Early Trial

                            Details : NN9487 (amycretin) is a novel oral, unimolecular co-agonist of both GLP-1 and amylin receptors that successfully completed phase 1 trial in Japanese Participants with Obesity

                            Product Name : NN9487

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            October 09, 2024

                            Lead Product(s) : Amycretin

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Cytoki Pharma

                            Denmark arrow
                            EPS
                            Not Confirmed

                            Cytoki Pharma

                            Denmark arrow
                            EPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CK-0045

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Cytoki Pharma Announces Positive Phase 1 Data for CK-0045 in Cardiometabolic Risk Factors

                            Details : CK-0045 is a long-acting analogue of interleukin-22 (IL-22), an atypical, non-immunomodulatory cytokine that selectively targets epithelial cells, is being evaluated for obesity & type 2 diabetes.

                            Product Name : CK-0045

                            Product Type : Other Large Molecule

                            Upfront Cash : Inapplicable

                            July 23, 2024

                            Lead Product(s) : CK-0045

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Novo Nordisk

                            Denmark arrow
                            EPS
                            Not Confirmed

                            Novo Nordisk

                            Denmark arrow
                            EPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Amycretin

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Novo Nordisk’s Obesity Pill Bests Wegovy in Early Trial

                            Details : NN9487 (amycretin) is a novel oral, unimolecular co-agonist of both GLP-1 and amylin receptors that successfully completed phase 1 trial in Japanese Participants with Obesity

                            Product Name : NN9487

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            July 03, 2024

                            Lead Product(s) : Amycretin

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Zealand Pharma

                            Denmark arrow
                            EPS
                            Not Confirmed

                            Zealand Pharma

                            Denmark arrow
                            EPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Petrelintide

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Zealand's Petrelintide Shows Positive Phase 1b Results

                            Details : ZP8396 (petrelintide) is an potent long-acting amylin analogue designed to improve solubility, minimize fibrillation, holdin a potential for the treatment of overweight.

                            Product Name : ZP8396

                            Product Type : Peptide

                            Upfront Cash : Inapplicable

                            June 20, 2024

                            Lead Product(s) : Petrelintide

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Cytoki Pharma

                            Denmark arrow
                            EPS
                            Not Confirmed

                            Cytoki Pharma

                            Denmark arrow
                            EPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CK-0045

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Cytoki Pharma Doses First Patient in Phase 2 Trial of CK-0045 for Obesity and Diabetes

                            Details : CK-0045 is a long-acting analogue of interleukin-22 (IL-22), an atypical, non-immunomodulatory cytokine that selectively targets epithelial cells, is being evaluated for obesity & type 2 diabetes.

                            Product Name : CK-0045

                            Product Type : Other Large Molecule

                            Upfront Cash : Inapplicable

                            April 11, 2024

                            Lead Product(s) : CK-0045

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth